Fentanyl Transdermal Patch and Ritonavir: Interaction Details

Brand names
Ritonavir
Norvir
Fentanyl Transdermal Patch
DuragesicAbstralSubsys +3 more
Same medicines, other forms
Dr. Brian Staiger, PharmD, BCPS

Medically reviewed by ⁠

Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page

A close look at the Fentanyl Transdermal Patch and Ritonavir interaction:

Share

Share this interaction

Fentanyl Transdermal Patch

Brand names
  • Duragesic
  • Abstral
  • Subsys
  • Ionsys
  • Actiq
  • Fentora

What Happens When You Take Fentanyl Transdermal Patch With Ritonavir

What can happen when they are taken together (rated Major)

Increased fentaNYL exposure and an increased risk of prolonged effects

Interaction Deep Dive

A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →

When fentaNYL is taken together with a , fentaNYL can rise, which may intensify or prolong opioid effects. This is especially likely if the inhibitor is introduced after the patient has already reached a stable fentaNYL dose.

Where the combination cannot be avoided, a lower fentaNYL dosage should be considered until effects have stabilized, and patients should be assessed often for and . The reverse situation arises when a CYP3A4 inhibitor is stopped: as its inhibitory effect wanes, fentaNYL plasma concentrations fall, which can reduce opioid or precipitate a withdrawal syndrome in patients who have become physically dependent on fentaNYL. In that case, consider raising the fentaNYL dosage until stable effects are reached, and monitor for signs of opioid withdrawal.4231

The Fentanyl Transdermal Patch and Ritonavir Interaction, Explained

Ritonavir (Norvir) can slow down the way your body breaks down fentanyl, the strong pain medicine in the Duragesic patch. That means more fentanyl can build up in your blood, and its effects can be stronger and last longer than expected. This can cause extra sleepiness, slow or shallow breathing, and confusion.

The risk is highest when ritonavir is started after your patch dose is already steady. Stopping ritonavir can also matter, since fentanyl levels can drop and pain or withdrawal symptoms may show up. Please don't change anything on your own. Your pharmacist and doctor can adjust your fentanyl dose and check on you more often to keep you safe and comfortable.

Mechanism: Ritonavir is a potent and fentanyl is a CYP3A4 (active drug, not dependent on activation). reduces fentanyl , increasing exposure and prolonging effects, including with transdermal systems. Evidence is established; severity is major; onset is unspecified.

  • Risk: and , especially when the inhibitor is added to a stable fentanyl dose.
  • Management: if is necessary, consider reducing the fentanyl dose until stable effects are achieved, and assess frequently for respiratory depression and sedation.
  • On discontinuation of ritonavir: fentanyl levels fall, risking reduced analgesia or withdrawal; consider increasing the fentanyl dose until effects stabilize and monitor for withdrawal.

See the 8 references behind this explanation ↓

From the HelloPharmacist Pharmacy Team

AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .

How we build these pages · How we use AI · Our editorial policy

Why Fentanyl Transdermal Patch and Ritonavir Interact

The likely mechanism

of -mediated of fentaNYL

In short: Ritonavir slows CYP3A4, an enzyme that breaks down fentanyl, so fentanyl can build up in the body.
How Drug Interactions Work See this kind of interaction drawn out, step by step, in “When One Drug Raises Another’s Level”, one chapter of our one-minute explainer. See how it works 

How to Manage the Fentanyl Transdermal Patch and Ritonavir Interaction

Your care team can manage this by tailoring your fentanyl dose and monitoring you closely.

  • Keep using both medicines as prescribed unless your prescriber tells you otherwise.
  • Your team may lower your fentanyl dose until your effects are steady, and check you often for sleepiness and slowed breathing.
  • If ritonavir is ever stopped, your fentanyl dose may need to be raised, and your team will watch for withdrawal signs or returning pain.
  • Tell your pharmacist or doctor before starting or stopping ritonavir or any other medicine.
  • Seek urgent help for extreme drowsiness, trouble waking, or very slow breathing.

Management is individual — confirm any change with your pharmacist or prescriber.

Questions for Your Pharmacist

  • Does my dose of Fentanyl Transdermal Patch or Ritonavir need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there another option that avoids this interaction?

Literature Reports

5 reports from the published literature. Each one is headed by the title of the published study it comes from.

What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.

  1. Report 1 · Study title

    Prescribing information: DIFLUCAN oral tablets, suspension, fluconazole oral tablets, suspension

    A single fatal case of a possible fentaNYL-fluconazole interaction has been reported, and the author concluded that the patient died of fentaNYL intoxication. In addition, a randomized crossover study in 12 healthy volunteers found that fluconazole significantly slowed the of fentaNYL. Higher fentaNYL concentrations may result in .6

  2. Report 2 · Study title

    Ritonavir's role in reducing fentanyl clearance and prolonging its half-life

    Twelve healthy volunteers were given either placebo or oral ritonavir 3 times daily for 3 days, and fentaNYL 5 mcg/kg IV was administered after the second ritonavir dose on day 2. Naloxone was given before and together with the fentaNYL dose to prevent the sedative and respiratory depressant effects of fentaNYL.

    One subject withdrew from the study before receiving fentaNYL. Among the 11 remaining participants, ritonavir reduced the plasma of fentaNYL by 67% (from 15.6 to 5.2 mL/min/kg).

    Compared with placebo, the of fentaNYL rose from 9.4 hours to 20.1 hours after ritonavir, and the area under the concentration-time curve () rose by 174% (from 6.6 to 18.1 ng/mL/hr). Ritonavir is considered likely to affect the elimination of transdermally administered fentaNYL in a similar way.5

  3. Report 3 · Study title

    Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl

    In an open, randomized, crossover study, giving fluconazole with a single IV dose of fentaNYL lowered the mean plasma of fentaNYL by 16%. Twelve healthy volunteers received a single IV dose of fentaNYL 5 mcg/kg, either alone (control phase) or 1 hour after the last fluconazole dose on day 2 (400 mg orally once daily on day 1, then 200 mg orally once daily on day 2).

    Naloxone was given before and with the fentaNYL dose to prevent the sedative and respiratory depressant effects of fentaNYL. All 12 subjects finished the study.

    In the fluconazole phase, mean plasma clearance was 16% lower than in the control phase (range, -34% to 53%; p less than 0.05). The fentaNYL showed a nonsignificant rise (fluconazole phase, 7.7 +/- 2.3 nanograms (ng) x hr/mL vs control phase 6.1 +/- 1.1 ng x hr/mL), whereas the inactive norfentaNYL fell markedly (fluconazole phase, 0.8 +/- 0.7 ng x hr/mL vs control phase, 1.8 +/- 1.1 ng x hr/mL).

    The ratio of norfentaNYL AUC to fentaNYL AUC was significantly lower in the fluconazole phase than in the control phase (AUC ratio, 0.1 +/- 0.1 vs 0.3 +/- 0.2). Mean of fentaNYL was the same in both phases. The altered fentaNYL clearance seemed to result from of -mediated N-dealkylation of fentaNYL to norfentaNYL.7

  4. Report 4 · Study title

    Possible fluconazole-fentanyl interaction-a case report

    A 46-year-old man using transdermal fentaNYL died after concurrent treatment with fluconazole. He had oral pain from radiation therapy for tonsillar cancer and was treated with a fentaNYL 100 mcg/hr transdermal patch.

    Over the following 1.5 months, the fentaNYL dose was raised to 150 mcg/hr. His medications included morphine 10 mg orally once daily, diclofenac 50 mg orally 3 times daily, paracetamol 1000 mg orally 3 times daily, oxazepam 15 mg orally twice daily, zolpidem 5 mg orally nightly, nystatin (100,000 international units/mL) 4 times daily, metoclopramide 20 mg rectally 3 times daily, lidocaine oral spray, and lactulose.

    Two weeks after the increase to fentaNYL 150 mcg/hr, he had a percutaneous gastrostomy because of worsening dysphagia. Eight days later he developed an oral fungal infection and was started on oral fluconazole 50 mg/day.

    Three days after that, he died in his sleep. Forensic analysis showed a toxic fentaNYL concentration (0.017 mcg/g), high concentrations of fluconazole (2.4 mcg/g), lidocaine (1.6 mcg/g), and metoclopramide (0.15 mcg/g), and a therapeutic zolpidem concentration.

    No ethanol or drugs of abuse were detected. The only autopsy findings were pulmonary congestion and brain edema. There was no indication of intentional overdose, and the coroner concluded that the cause of death was and circulatory failure due to fentaNYL intoxication.8

  5. Report 5 · Study title

    Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl

    In an open, randomized, crossover study, giving voriconazole with a single IV dose of fentaNYL raised the mean of fentaNYL 1.4-fold and lowered the mean plasma by 23%. Twelve healthy volunteers received a single IV dose of fentaNYL 5 mcg/kg, either alone (control phase) or 1 hour after the final voriconazole dose on day 2 (400 mg orally twice daily on day 1, then 200 mg orally twice daily on day 2).

    Naloxone was given before and with the fentaNYL dose to prevent the sedative and respiratory depressant effects of fentaNYL. All 12 subjects finished the study.

    In the voriconazole phase, the mean AUC (0 to infinity) of fentaNYL was 1.4-fold higher (range, 0.81- to 2.04-fold) and the mean plasma clearance was 23% lower (range -22% to 48%) than in the control phase. Of note, the mean fentaNYL at 12 hr in the voriconazole phase was equal to that at 6 hr in the control phase.

    Mean of fentaNYL again did not differ between phases. Nausea and vomiting occurred in 4 subjects during the voriconazole phase and in 2 subjects during the control phase. No additional naloxone doses were needed, and no other adverse events were reported.7

Fentanyl Transdermal Patch and Ritonavir: Common Questions

How serious is the Fentanyl Transdermal Patch and Ritonavir interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How is the Fentanyl Transdermal Patch and Ritonavir interaction managed?

Your care team can manage this by tailoring your fentanyl dose and monitoring you closely. Keep using both medicines as prescribed unless your prescriber tells you otherwise. Your team may lower your fentanyl dose until your effects are steady, and check you often for sleepiness and slowed breathing. If ritonavir is ever stopped, your fentanyl dose may need to be raised, and your team will watch f… Management is individual — always follow your own care team's guidance.

Does taking Fentanyl Transdermal Patch and Ritonavir at different times of day help?

No. Taking them at different times of day does not prevent this one. Ritonavir slows , an enzyme that breaks down fentanyl, so fentanyl can build up in the body. That change lasts while ritonavir is being taken and can continue for a while after the last dose.

Your pharmacist or prescriber can tell you how they will manage it.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "established". Well documented — supported by controlled studies or strong clinical data.

Ask About the Fentanyl Transdermal Patch and Ritonavir Interaction

Ask in your own words about taking Fentanyl Transdermal Patch and Ritonavir together. The answer comes from this page’s interaction record and both drugs’ own information.

This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.

Try:

AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.

References (8)

  1. Product Information: DURAGESIC(R) transdermal system, fentanyl transdermal system. Janssen Pharmaceuticals Inc (per manufacturer), Titusville, NJ, 2018. DailyMed
  2. Product Information: ACTIQ(R) oral transmucosal lozenge, fentanyl citrate oral transmucosal lozenge. Teva Pharmaceuticals USA, Inc. (per FDA), Parsippany, NJ, 2023. DailyMed
  3. Product Information: Fentanyl citrate intravenous, intramuscular injection, fentanyl citrate intravenous, intramuscular injection. Hospira Inc (per FDA), Lake Forest, IL, 2023. DailyMed
  4. Product Information: FENTORA(R) buccal tablets, fentanyl citrate buccal tablets. Teva Pharmaceuticals USA Inc (per FDA), Parsippany, NJ, 2023.
  5. Olkkola KT, Palkama VJ, & Neuvonen PJ: Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. Anesthesiology 1999; 91:681-685. PubMed
  6. Product Information: DIFLUCAN(R) oral tablets, suspension, fluconazole oral tablets, suspension. Roerig (per FDA), New York, NY, 2023. DailyMed
  7. Saari TI, Laine K, Neuvonen M, et al: Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl. Eur J Clin Pharmacol 2008; 64(1):25-30. PubMed
  8. Hallberg P, Marten L, & Wadelius M: Possible fluconazole-fentanyl interaction-a case report. Eur J Clin Pharmacol 2006; 62(6):491-492. PubMed
Was this write-up helpful?

Other Serious Interactions of Fentanyl Transdermal Patch and Ritonavir

Also serious with Ritonavir

Also serious with Fentanyl Transdermal Patch

These Medications Also Interact With Supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

With Ritonavir

Check everything you take with our drug–supplement interaction checker.

Still Have Questions About This Combination?

Every question gets a real answer from a licensed pharmacist — free, as soon as they can.

About This Library

Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →

What Each Rating Means

Severity Levels

  • Contraindicated These should generally not be used together.
  • Major Potentially serious — often needs a change or close monitoring. This interaction.
  • Moderate Can be significant — usually manageable with monitoring.
  • Minor Usually limited clinical impact.

Evidence Grades

  • EstablishedWell documented — supported by controlled studies or strong clinical data. This interaction.
  • ProbableGood supporting evidence, though not definitively proven.
  • SuspectedSome evidence suggests this interaction, but it is not well established.
  • PossibleLimited or conflicting evidence; the interaction may occur.
  • TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.

How Soon It Shows

  • RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
  • DelayedEffects tend to build up gradually over days to weeks.
  • UnspecifiedThe timing of this interaction is not well characterized. This interaction.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Back to the answer
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.